Your peptide journey, with science, clinicians, and your health story working together.
Illustrative local data for the institutional concept. Select a card or use the up and down arrow keys to browse.
Decades of research have made peptide-based treatments part of modern care—from insulin to GLP-1 therapies. Already used by millions of people, this field continues to evolve with new therapeutic possibilities.
U.S. users · insulin + GLP-1
A directional model combines insulin and current GLP-1 use and subtracts estimated overlap. It is not a census of all peptide medicines. Lines connect dated model anchors; intermediate years are not measured observations.
2025 model: 8.5M insulin + 32.2M GLP-1 − 2.7M estimated overlap = 38.0M adults. These inputs include estimates; the total is not a directly surveyed count.
The dots show 12% of U.S. adults reporting current GLP-1 use in the March 2026 KFF poll, approximately 1 in 8. This survey measure is separate from the combined 2025 model above.
| Year | Adults (millions) |
|---|---|
| 2000 | 6.0 |
| 2005 | 6.5 |
| 2010 | 7.8 |
| 2015 | 9.4 |
| 2020 | 12.2 |
| 2022 | 15.0 |
| 2024 | 21.6 |
| 2025 | 38.0 |
Already part of millions of lives.
About 1 in 8
U.S. adults report
current GLP-1 use.
Research has led to approved peptide-based medicines across different areas of care. Each milestone marks another step from discovery to clinical practice.
U.S. FDA · Selected catalogue
Cumulative branded medicines
*Partial period · through September 2026
First approvals · 2024–2026 · 2 in this catalogue
A selected educational catalogue of 36 branded medicines and 32 distinct active ingredients, first approved from 2000 to September 2026. Bars accumulate this catalogue; they do not measure the approval rate or all FDA-approved peptide products.
One count per brand and original application. Ingredients are deduplicated by active moiety; brands sharing liraglutide, semaglutide or tirzepatide remain separate medicines. Supplemental indications, generics and later strengths are not additional approvals.
The scope includes peptide analogues, peptide-derived medicines and selected polypeptides. Trulicity is a GLP-1–Fc fusion protein; Kalbitor is a 60-amino-acid polypeptide. This is not a catalogue restricted to small peptides. RNA medicines such as Izervay, standalone antibodies and investigational compounds are excluded. Historical approval does not imply current availability.
Each medicine links to its FDA record. Indications are brief summaries of the initial approval, not the complete prescribing information. Forzinity received accelerated approval with a confirmatory trial requirement.
FDA approval records and methodology ↗What clinical studies found—and the context needed to understand each result.
NEJM · 2024
20 fewer apnea–hypopnea events per hour versus placebo. Adults with obstructive sleep apnea and obesity · SURMOUNT-OSA, trial 1 · 52 weeks
Adults with sleep apnea and obesity · Trial 1 · 52 weeks
Read the study : Fewer breathing interruptions.Paper previews are editorial adaptations from the existing Peptivius offer, based on the linked publications. Results describe the studied populations and do not predict individual outcomes. The Nature Chemistry item reports preclinical discovery, not clinical efficacy.
Courtesy portraits · TIME · 2024. Publication names and logos identify sources; they do not imply partnership or endorsement.
What studies found, and who they studied.
Weight management
20.9%
Mean reduction in body weight
Sleep apnea
20/h
Fewer apnea–hypopnea events per hour versus placebo
Intestinal support
63%
Reached the study’s response threshold
Bone health
9/100
Fewer new vertebral fractures per 100 participants
Sexual well-being
58%
Reported a perceived treatment benefit
Photoprotection
28.6h
More median pain-free time in direct sunlight
Cardiovascular outcomes
20%
Lower relative risk of major cardiovascular events
Neuromuscular function
2.09pts
Additional improvement in daily function versus placebo
Growth velocity
1.57cm/yr
Greater annualized growth velocity
Tumor progression
32.1pp
More participants progression-free at 24 months
Result 1 of 10: Weight management
Results apply to the studied populations, not an individual outcome. Each chart compares groups within one study, not medicines with each other.
Between promising science and everyday care, there are personal decisions, health information, and follow-up to connect.
Conflicting informationStudies, personal stories, and marketing can tell different stories.
JAMA · Research
Scattered health historyYour history, medicines, test results, and goals belong in the same picture.
Annals of Internal Medicine · Context in care
Unclear product statusA familiar name does not explain a product’s origin, approval status, or supported uses.
FDA · Unapproved GLP-1 medicines
Disconnected follow-upQuestions, treatment changes, and follow-up need a clear next step.
JAMA Network Open · Treatment continuityConflicting information becomes Evidence in context in the Peptivius vision.
Science, personal context, clinical care, and treatment access—connected around you.
01 — Your story · A simulated case
Erika starts by sharing her story.
Through Peptivius onboarding, she brings together her goals, health history, medications, and daily routine—creating the starting point for a more personal journey.
02 — At-home testing
After an initial review, Erika receives an at-home collection kit. Her sample is analyzed by a partner laboratory, and the results become part of her Peptivius health profile.
Erika receives her collection materials at home, with preparation and return instructions. Before she begins, she knows what to collect, how to handle it, and where it needs to go.
She prepares the sample following the kit’s instructions and seals the return packaging. A partner laboratory analyzes it, adding measured information to the health story she shared during onboarding.
Her results join her goals, medications, and health history. Together, they inform her Peptide Blueprint—a more complete starting point for understanding the evidence and discussing next steps with a clinician.
03 — Your Peptide Blueprint
Erika’s health story comes together in her Peptide Blueprint—a personalized view of the research, considerations, and questions to explore with her clinician.
Here, we follow her Weight Loss chapter.
04 — Clinical care
Peptivius arranges Erika’s consultation and brings her health context together. Her clinician reviews the full picture and decides whether medication is appropriate.
We coordinate the journey, from clinical review to medication access and delivery.
Clinical consultation
Connected by PeptiviusHer clinician reviews her Blueprint, medications, and goals before deciding what comes next.
A prescription only when appropriate.
05 — Medication delivery
When medication is prescribed, Peptivius coordinates pharmacy review, preparation, and delivery—keeping Erika informed along the way.
One connected journey, with her clinician’s guidance and follow-up in view.
06 — Connected care
Erika keeps her plan, health records, and daily check-ins together in Peptivius—so each next step builds on the full picture.
07 — Peptivius AI
Your health story keeps evolving. Peptivius brings new information and scientific evidence into the conversation.
Our scientific content draws on peer-reviewed publications and established biomedical references.
Research is the foundation. For Erika, its relevance depends on her health history, a clinician’s assessment, and the support that follows. Peptivius connects these pieces into a journey built around her.
With that full picture in mind, let’s return to Erika—and look at two ways her plan could take shape.
08 — The outcome
SAME PERSON. SAME GOALS. DIFFERENT PLANS.
Erika followed popular peptide options without a structured review of her medications, clinical conditions, or how the compounds might work together.
Erika used Peptivius to organize her goals, medications, and clinical history—surfacing trade-offs and better questions to discuss with a licensed clinician.
Persistent bloating, lower energy, reduced training performance, and ongoing hair and skin concerns.
Better lean-mass retention, stable energy, maintained strength, and fewer unresolved skin and hair concerns.
| Limited-context | Final result at 12 months | Peptivius-guided |
|---|---|---|
| 78 kg | Starting weight | 78 kg |
| ≈68 kg | Final weight | ≈63 kg |
| −10 kg (−12.8%) | Total change | −15 kg (−19.2%) |
| 35% → ≈30% | Estimated body fat | 35% → ≈26% |
| Some loss | Lean-mass trend | Better preserved |
| Reduced | Strength | Maintained |
| Frequently low | Energy | Generally stable |
| Persistent | Bloating | Mild and intermittent |
| Less supported | Skin appearance | Visually improved |
| Continued thinning | Hair density | Visually denser |
| Weight loss with unresolved trade-offs | Overall endpoint | More balanced illustrative result |
